-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Lewy body dementia (DLB) is one of the most common neurodegenerative dementias, second only to Alzheimer's disease (AD).
In addition to dementia, its characteristic clinical manifestations also include: visual hallucinations, Parkinson's syndrome, fluctuating cognitive impairment, autonomic dysfunction, sleep disorders, and sensitivity to antipsychotics.
The pathological feature of DLB is the presence of intracytoplasmic eosinophilic inclusion bodies (called Lewy bodies) in the deep cortex of the whole brain (especially the prefrontal lobe, anterior temporal lobe, cingulate gyrus and insula), which contain aggregated α -Synuclein (Aβ).
Studies have shown that compared with AD, DLB patients progress faster, have a higher hospitalization rate, and have a worse prognosis.
Studies have shown that compared with AD, DLB patients progress faster, have a higher hospitalization rate, and have a worse prognosis.
In order to determine whether the clinical progression rates associated with MCI-LB or MCI-AD are different, experts from the University of Cambridge in the United Kingdom conducted longitudinal observations on MCI cases and conducted detailed clinical evaluations of the diagnostic features of Lewy bodies.
Researchers annually evaluate a prospective longitudinal cohort of 111 MCI patients ≥60 years of age to track cognitive and clinical progress, including core clinical characteristics and DLB biomarkers.
Survival curve of MCI patients with visual hallucinations or cognitive fluctuations at baseline
Survival curve of MCI patients with visual hallucinations or cognitive fluctuations at baselineAfter an average follow-up of 2.
The existence of any feature of Lewy body disease is related to the risk of transition to dementia; as more diagnostic features are observed, this risk further increases (OR=1.
The relationship between age and the existence of Lewy body characteristics in the transition from MCI to death or dementia.
The relationship between age and the existence of Lewy body characteristics in the transition from MCI to death or dementia.
Further in the additional analysis to control the use of cholinesterase inhibitors, the association between cognitive fluctuations and the onset of dementia (HR=2.
In summary, the diagnostic features of Lewy body dementia are related to the increased risk of transition from mild cognitive impairment to dementia.
references:
Progression to Dementia in Mild Cognitive Impairment With Lewy Bodies or Alzheimer Disease.
Progression to Dementia in Mild Cognitive Impairment With Lewy Bodies or Alzheimer Disease.
Leave a message here
